1. Volume 65, Issue 3, Pages 516-520 (March 2014)
A Randomised Phase 2 Study Combining LY Sodium (Survivin Antisense Oligonucleotide) with First-line Docetaxel/Prednisone in Patients with Castration- resistant Prostate Cancer 
Paweł Wiechno, Bradley G. Somer, Begoña Mellado, Piotr L. Chłosta, José Manuel Cervera Grau, Daniel Castellano, Christoph Reuter, Michael Stöckle, Jörn Kamradt, Joanna Pikiel, Ignacio Durán, Steffen Wedel, Sophie Callies, Valérie André, Karla Hurt, Jacqueline Brown, Michael Lahn, Bernhard Heinrich 
European Urology 
Volume 65, Issue 3, Pages (March 2014)
DOI: /j.eururo
Copyright © 2013 European Association of Urology Terms and Conditions

2. Fig. 1
Consolidated Standards of Reporting Trials diagram. Of 194 patients entered, 40 patients did not meet the inclusion criteria. The remaining 154 patients were randomised into experimental (n=102) and control (n=52) arms. Patients were followed until death.
European Urology  , DOI: ( /j.eururo )
Copyright © 2013 European Association of Urology Terms and Conditions

3. Fig. 2
Influence on progression-free survival (PFS), as demonstrated by Kaplan-Meier graphs of comparisons by treatment arm, disease stage, prostate-specific antigen (PSA) level, and circulating tumour cell (CTC) level and by forest plot of several comparisons: (A) Kaplan-Meier graph for PFS comparison by treatment arm; (B) Kaplan-Meier graph for PFS comparison by disease stage at initial diagnosis, showing that patients with initial lower stage had a shorter PFS; (C) Kaplan-Meier graph for PFS comparison by baseline PSA level, in which “low” and “high” denote PSA levels relative to the median; (D) Kaplan-Meier graph for PFS comparison by CTC level; (E) hazard ratios (HRs) and their 90% confidence intervals are depicted for each baseline factor relative to the reference group (column on far right). HR estimates >1 indicate a decrease in PFS relative to the reference group. Histopathologic diagnosis grade: 1=well differentiated, 2=moderately differentiated, 3=poorly differentiated, and 4=undifferentiated.
BSA=body surface area; CRP=C-reactive protein; CTC=circulating tumour cells; DUR=duration since initial diagnosis; ECOG PS=Eastern Cooperative Oncology Group performance status; PFS=progression-free survival; PSA=prostate-specific antigen; RT=radiation therapy.
** Corresponds to continuous variables split at their median.
European Urology  , DOI: ( /j.eururo )
Copyright © 2013 European Association of Urology Terms and Conditions